Application No.: 10/619755 Docket No.: MXI-024CPDVCN2

REMARKS

Claim Amendments

Claims 1-40 were pending. Claims 1-40 have been canceled without prejudice. New claims 41-59 have been added. Support for new claims 41-59 can be found throughout the specification as originally filed. Accordingly, claims 41-59 are currently pending.

No new matter has been added. Any amendment and/or cancellation of the claims should in no way be construed as an acquiescence to any of the Examiner's rejections and was performed solely in the interest of expediting prosecution of the application. Applicants reserve the right to pursue the claims as originally filed or similar claims in this or a separate application(s).

Restriction Requirement

The Examiner has required restriction among the following inventions in the aboveidentified application:

Group I: claims 1-14 and 40, drawn to a method of stimulating an immune

response comprising the administration of a binding agent and an agent,

classified in class 424, subclass 178.1, for example;

Group II: claims 15-37, drawn to a molecular complex comprising an antigen

binding agent, classified in class 530, subclass 402, for example;

Group III: claim 38, drawn to a bispecific antibody, classified in class 530, subclass

387.3.

Group IV: claim 39, drawn to a method of depleting antigen in the circulation

comprising the administration of the bispecific antibody of group III,

classified in class 424, subclass 136.1

Applicants hereby elect without traverse Group I (claims 1-14 and 40). Applicants further elect a tumor associated antigen.

As described above, claims 1-40 have been canceled. New claims 41-59 have been added. New claims 41-59 are drawn to methods of enhancing antigen presentation or targeting an antigen to an immune cell (e.g., an APC) through the administration of a complex comprising

Application No.: 10/619755 Docket No.: MXI-024CPDVCN2

an antigen and a binding agent which binds to FcγRI on an APC. Accordingly, the methods of claims 41-59 stimulate an immune response by administering an antigen and a binding agent, as defined by Group I. Based on the foregoing, Applicants' election of Group I includes an election to prosecute claims 41-59.

CONCLUSION

If a telephone conversation with Applicants' attorney would help expedite the prosecution of the above-identified application, the Examiner is urged to call Applicants' attorney at (617) 227-7400.

Dated: August 19, 2005

Respectfully submitted,

Jeanne\M. DiGiorgio

Registration No.: 41,710

LAHIVE & COCKFIELD, LLP

28 State Street

Boston, Massachusetts 02109

(617) 227-7400

(617) 742-4214 (Fax)

Attorney/Agent For Applicant